A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

What is the purpose of this trial?

Brief Summary:
This study will evaluate the efficacy of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for F508del and a minimal function mutation (F/MF subjects)

Participation Guidelines

Ages: 12 years and older

Gender: Both

Vertex Pharmaceuticals Incorporated

Start Date: 05/17/2018

End Date: 04/16/2019

Last Updated: 07/10/2018

Study HIC#: 2000022732

Get Involved

For more information about this study, contact:
Catalina Guzman
+1 203-836-7172

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image


Marie Egan

Principal Investigator